If disease of a patient with angioedema and no identified variant fails to show a response to 4-fold the maximum guideline-stated dose of an antihistamine, some clinicians would add in the anti-IgE monoclonal antibody omalizumab as the next step; this is included in a recent expert consensus.14 The gene discussed is IGHE; the disease is angioedema.